The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Intratumoral cellular immunotherapy with autologous SIRPα-low macrophages in NHL: Phase I findings
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a Phase I trial (NCT05967416) investigating intratumoral cellular immunotherapy with autologous hyperactivated M1 SIRPα-low macrophages in non-Hodgkin lymphoma (NHL). Dr Strati highlights that this innovative cellular therapy has the potential to target lymphoma cells independently of specific antigens, addressing a major limitation of current options, and notes that future studies will focus on optimizing the dose and frequency of injections to achieve more complete and durable remissions. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
